ArticleAnnals of hematology2025
Revisiting hepatitis B vaccination in children with transfusion-dependent thalassemia.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thalassemia is a common hereditary hemoglobinopathy found largely in the "Thalassemia Belt". Thalassemia children are at risk of the hepatitis B virus (HBV) infection, given the frequent need for blood transfusions. The immune dysregulation underlying these diseases may lead to defective long-term protection even after full HBV vaccination. This study will evaluate the efficacy of an additional hepatitis B vaccine and will screen the influencing factors that affect immune responses of thalassemia children. All subjects were screened from August 2023 to July 2024 at Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia, where 126 pediatric patients (3-18 years of age) were diagnosed with thalassemia. All the participants had previously received the Indonesian national hepatitis B vaccination program. Seventy two eligible children who exhibited negative immune protection against hepatitis B accordingly received a single booster dose of hepatitis B vaccine. One month later the immune response was assessed by determination of anti-HBs titers. Logistic regression was used to evaluate significant predictors of the anti-HBs titer. Age, gender, type of thalassemia, transfusion interval, ferritin levels, nutritional status, and splenectomy were compared with post vaccine anti-HBs levels. Following the booster, protective immunity was present in 75% of children and high protective titers were present in 50%. The predictors of post-booster anti-HBs level included age (OR = 0.5; CI = 0.2-0.8; p = 0.018) and splenectomy. Children with transfusion-dependent thalassemia, aged over 3 years, are recommended to receive a booster dose of the hepatitis B vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.